DE602006019582D1 - Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen - Google Patents
Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungenInfo
- Publication number
- DE602006019582D1 DE602006019582D1 DE602006019582T DE602006019582T DE602006019582D1 DE 602006019582 D1 DE602006019582 D1 DE 602006019582D1 DE 602006019582 T DE602006019582 T DE 602006019582T DE 602006019582 T DE602006019582 T DE 602006019582T DE 602006019582 D1 DE602006019582 D1 DE 602006019582D1
- Authority
- DE
- Germany
- Prior art keywords
- adarb2
- disease
- alzheimer
- diagnostic
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
- C12Q2535/101—Sanger sequencing method, i.e. oligonucleotide sequencing using primer elongation and dideoxynucleotides as chain terminators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69086205P | 2005-06-16 | 2005-06-16 | |
EP05105316 | 2005-06-16 | ||
PCT/EP2006/063215 WO2006134128A2 (en) | 2005-06-16 | 2006-06-14 | Diagnostic and therapeutic target adarb2 proteins for neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602006019582D1 true DE602006019582D1 (de) | 2011-02-24 |
Family
ID=35355216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602006019582T Active DE602006019582D1 (de) | 2005-06-16 | 2006-06-14 | Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen |
Country Status (6)
Country | Link |
---|---|
US (1) | US20100008921A1 (de) |
EP (1) | EP1891241B1 (de) |
JP (1) | JP2008546379A (de) |
AT (1) | ATE495269T1 (de) |
DE (1) | DE602006019582D1 (de) |
WO (1) | WO2006134128A2 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2162550B1 (de) * | 2007-06-13 | 2017-08-09 | Alcediag | Periphere gewebeprobe mit 5htr2c und/oder adar exprimierenden zellen als marker für die änderung des mechanismus der 5htr2c-mrna-prozessierung sowie anwendungen davon |
WO2009007934A2 (en) | 2007-07-10 | 2009-01-15 | Neurim Pharmaceuticals (1991) Ltd. | Cd44 splice variants in neurodegenerative diseases |
EP2202321A1 (de) * | 2008-12-17 | 2010-06-30 | Biocortech | Beurteilung des potentiellen Risikos von durch Arzneimittel ausgelösten Stimmungsstörungen und Selbstmord, Verwendung einer dafür vorgesehenen Plattform |
US10456493B2 (en) | 2017-06-23 | 2019-10-29 | Allied Bioscience, Inc. | Infection control apparatus |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763174A (en) * | 1994-02-17 | 1998-06-09 | The Wistar Institute Of Anatomy & Biology | RNA editing enzyme and methods of use thereof |
DE4438391C2 (de) | 1994-10-27 | 1997-07-03 | Evotec Biosystems Gmbh | Vorrichtung zur Bestimmung stoffspezifischer Parameter eines oder weniger Moleküle mittels Korrelations-Spektroskopie |
EP0836090A1 (de) | 1996-10-12 | 1998-04-15 | Evotec BioSystems GmbH | Probenanalyseverfahren durch Bestimmung der spezifischen Helligkeitsverteilung von Teilchen |
DE19649048C1 (de) | 1996-11-27 | 1998-04-09 | Evotec Biosystems Gmbh | Verfahren zur Unterscheidung oder Erfassung von Partikeln in einer Probe durch Identifizierung von Signalabschnitten zeitaufgelöster, optischer Rohsignale aus der Probe auf Basis von Einzelphotonendetektion |
EP0945718A1 (de) | 1998-03-21 | 1999-09-29 | Evotec BioSystems AG | Ein Verfahren zur Probencharakterisierung durch Bestimmung einer Funktion mindestens einer spezifischen Eigenschaft von Einheiten der Probe |
ATE208037T1 (de) | 1997-12-23 | 2001-11-15 | Evotec Biosystems Ag | Verfahren zum nachweis von reaktionen mittels koinzidenzanalyse |
WO2000052451A1 (en) | 1999-03-03 | 2000-09-08 | Evotec Analytical Systems Gmbh | Homogeneous fluorescence assay |
DK1175602T3 (da) | 1999-04-29 | 2003-05-26 | Evotec Ag | Fremgangsmåde til karakterisering af fluorescente molekyler eller andre partikler, der anvender frembringerfunktioner |
WO2001059416A1 (en) | 2000-02-10 | 2001-08-16 | Evotec Oai Ag | Fluorescence intensity multiple distributions analysis: concurrent determination of diffusion times and molecular brightness |
US6690463B2 (en) | 2000-02-10 | 2004-02-10 | Evotec Biosystems Ag | Fluorescence intensity and lifetime distribution analysis |
DE10030798A1 (de) | 2000-06-29 | 2002-01-10 | Evotec Analytical Sys Gmbh | Kompetitives Assay-Verfahren |
EP1313876B8 (de) | 2000-08-11 | 2007-02-28 | Evotec AG | Verfahren zum nachweis von acetylase oder deacetylase aktivität in einem immunoassay |
-
2006
- 2006-06-14 AT AT06777334T patent/ATE495269T1/de not_active IP Right Cessation
- 2006-06-14 US US11/922,060 patent/US20100008921A1/en not_active Abandoned
- 2006-06-14 DE DE602006019582T patent/DE602006019582D1/de active Active
- 2006-06-14 JP JP2008516310A patent/JP2008546379A/ja not_active Withdrawn
- 2006-06-14 WO PCT/EP2006/063215 patent/WO2006134128A2/en not_active Application Discontinuation
- 2006-06-14 EP EP06777334A patent/EP1891241B1/de active Active
Also Published As
Publication number | Publication date |
---|---|
ATE495269T1 (de) | 2011-01-15 |
EP1891241B1 (de) | 2011-01-12 |
EP1891241A2 (de) | 2008-02-27 |
JP2008546379A (ja) | 2008-12-25 |
US20100008921A1 (en) | 2010-01-14 |
WO2006134128A2 (en) | 2006-12-21 |
WO2006134128A3 (en) | 2007-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005108999A3 (en) | Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease | |
ATE530667T1 (de) | Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit | |
ATE461941T1 (de) | Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation | |
WO2001075454A3 (en) | Diagnosis and treatment of alzheimer's disease | |
ATE361067T1 (de) | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen | |
WO2003028543A3 (en) | Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease | |
DE602006019582D1 (de) | Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen | |
WO2004070388A8 (en) | Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases | |
WO2006091964A3 (en) | Regulators of protein misfolding and aggregation and methods of using the same | |
WO2004001422A3 (en) | Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases | |
WO2002016636A3 (en) | Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders | |
ATE534751T1 (de) | Verwendung von prkx zur diagnose und therapie von alzheimer krankheit | |
ATE449964T1 (de) | DIAGNOSTISCHE VERWENDUNG VON ßENSADIN-0477ß FÜR NEURODEGENERATIVE ERKRANKUNGEN | |
WO2004038411A3 (en) | Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases | |
ATE458834T1 (de) | Diagnostische und therapeutische verwendung des mal2-gens und proteins bei neurodegenerativen krankheiten | |
WO2006131562A3 (en) | Diagnostic and therapeutic target cdc2l6 gene and proteins for neurodegenerative diseases | |
DE60235996D1 (de) | Diagnostische und therapeutische verwendung von f-box-proteinen bei morbus alzheimer und verwandten neurodegenerativen erkrankungen | |
WO2005030947A3 (en) | Diagnostic and therapeutic use of a sulfotransferase for neurodegenerative diseases | |
WO2005101014A3 (en) | Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases | |
WO2005059562A3 (en) | Diagnostic and therapeutic use of the human hif3alpha gene and proteins for neurodegenerative diseases | |
ATE316657T1 (de) | Diagnostische und therapeutische verwendung des caps | |
DE60314497D1 (de) | Diagnostische und therapeutische verwendung von humanen maguinproteinen und nukleinsäuren bei neurodegenerativen krankheiten | |
WO2006008294A3 (en) | Diagnostic and therapeutic use of slim3 for neurodegenerative diseases | |
WO2003085131A3 (en) | Diagnostic and therapeutic use of vault polynucleotides and proteins for neurodegenerative diseases | |
DE60227650D1 (de) | Verwendung eines zum kern beschränkten protein für die diagnose und therapie von alzheimer-krankheit und relatierte neurodegeneratiefe störungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R082 | Change of representative |
Ref document number: 1891241 Country of ref document: EP Representative=s name: VON KREISLER SELTING WERNER, DE |